DK1866342T3 - Separation af forurenende kontaminanter fra streptococcus pneumoniae-polysaccharid ved ph-manipulation - Google Patents
Separation af forurenende kontaminanter fra streptococcus pneumoniae-polysaccharid ved ph-manipulation Download PDFInfo
- Publication number
- DK1866342T3 DK1866342T3 DK06740302.2T DK06740302T DK1866342T3 DK 1866342 T3 DK1866342 T3 DK 1866342T3 DK 06740302 T DK06740302 T DK 06740302T DK 1866342 T3 DK1866342 T3 DK 1866342T3
- Authority
- DK
- Denmark
- Prior art keywords
- polysaccharide
- precipitate
- solution
- lysate
- detergent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Polymers & Plastics (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Sustainable Development (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Claims (8)
1. Fremgangsmåde til at reducere proteinindholdet og opretholde kapselpo-lysaccharid-indholdet i en kompleks cellulær Streptococcus pneumoniae-lysatsuppe før oprensning, hvor fremgangsmåden omfatter følgende trin: (a) at udvide en udvalgt S. pneumoniae-serotype i stigende voluminer fra en begyndelsesbeholder til en beholder i produktionsskala i et sojabaseret medium og opretholde en stabil pH-værdi og temperatur under cellevækst; (b) at lysere bakteriecellerne produceret i trin (a) med en detergent, hvorved et lysat produceres, der indeholder opløselige proteiner, celledebris, nukleinsyrer og polysaccharid; (c) at omrøre det cellulære lysat i et tidsrum, der er tilstrækkeligt til at sikre komplet lysis- og polysaccharidfrigivelse; (d) at reducere pH-værdien af det cellulære lysat til mindre end 5,5 for at udskille detergentet og det meste af de opløselige proteiner; (e) at holde opløsningen og præcipitatet dannet i trin (d) uden omrøring i et tidsrum, der er tilstrækkeligt til at tillade bundfældning af præcipitatet, og (f) at behandle opløsningen og præcipitatet ved centrifugering og/eller filtrering, hvorved kapselpolysaccharidet i opløsningen fastholdes, og det opløselige protein reduceres effektivt.
2. Fremgangsmåde ifølge krav 1, hvor den udvalgte S. pneumoniae-serotype er 1,4, 5, 6A, 6B, 7F eller 19A.
3. Fremgangsmåde ifølge krav 1, hvor pH-værdien i trin (a) opretholdes afen basetilførsel af natriumhydroxid, natriumcarbonat eller en kombination deraf.
4. Fremgangsmåde ifølge krav 1, hvor fremgangsmåden omfatter trinnene: (a) at udvide i stigende voluminer fra en begyndelsesbeholder til en beholder i produktionsskala i et sojabaseret medium et S. pneumoniae-serotype udvalgt fra gruppen bestående af serotyper 1,4, 6A, 6B og 7F og opretholde en stabil pH-værdi og temperatur under cellevækst, hvor pH-værdien opretholdes med natriumhydroxid; (b) at lysere bakteriecellerne produceret i trin (a) med en detergent, hvorved et lysat produceres, der indeholder opløselige proteiner, celledebris, nukleinsyrer og polysaccharid; (c) at omrøre det cellulære lysat i et tidsrum, der er tilstrækkeligt til at sikre komplet lysis- og polysaccharidfrigivelse; (d) at reducere pH-værdien af det cellulære lysat til mindre end 5,5 for at udskille detergentet og det meste af de opløselige proteiner; (e) at holde opløsningen og præcipitatet dannet i trin (d) uden omrøring i et tidsrum, der er tilstrækkeligt til at tillade bundfældning af præcipitatet; og (f) at behandle opløsningen og præcipitatet ved centrifugering og/eller filtrering, hvorved kapselpolysaccharidet i opløsningen fastholdes, og det opløselige protein reduceres effektivt.
5. Fremgangsmåde ifølge krav 1, hvor fremgangsmåden omfatter trinnene: (a) at udvide i stigende voluminer S. pneumoniae-serotype 5 fra en begyndelsesbeholder til en beholder i produktionsskala i et sojabaseret medium suppleret med natriumbikarbonat og opretholde en stabil pH-værdi og temperatur under cellevækst, hvor pH-værdien opretholdes med natriumhydroxid; (b) at lysere bakteriecellerne produceret i trin (a) med en detergent, hvorved et lysat produceres, der indeholder opløselige proteiner, celledebris, nukleinsyrer og polysaccharid; (c) at omrøre det cellulære lysat i et tidsrum, der er tilstrækkeligt til at sikre komplet lysis- og polysaccharidfrigivelse; (d) reducere pH-værdien for det cellulære lysat til mindre end 5,5 for at udfælde detergentet og det meste af de opløselige proteiner; (e) at holde opløsningen og præcipitatet dannet i trin (d) uden omrøring i et tidsrum, der er tilstrækkeligt til at tillade bundfældning af præcipitatet; og (f) at behandle opløsningen og præcipitatet ved centrifugering og/eller filtrering, hvorved kapselpolysaccharidet i opløsningen fastholdes, og det opløselige protein reduceres effektivt.
6. Fremgangsmåde ifølge krav 1, hvor fremgangsmåden omfatter trinnene: (a) at udvide i stigende voluminer S. pneumoniae serotype 19Afra en begyndelsesbeholder til en beholder i produktionsskala i et sojabaseret medium suppleret med natriumbikarbonat og opretholde en stabil pH-værdi og temperatur under cellevækst, hvor pH-værdien opretholdes med natriumcarbonat; (b) at lysere bakteriecellerne produceret i trin (a) med en detergent, hvorved et lysat produceres, der indeholder opløselige proteiner, celledebris, nukleinsyrer og polysaccharid; (c) at omrøre det cellulære lysat i et tidsrum, der er tilstrækkeligt til at sikre komplet lysis- og polysaccharidfrigivelse; (d) at reducere pH-værdien af det cellulære lysat til mindre end 5,5 for at udskille detergentet og det meste af de opløselige proteiner; (e) at holde opløsningen og præcipitatet dannet i trin (d) uden omrøring i et tidsrum, der er tilstrækkeligt til at tillade bundfældning af præcipitatet, og (f) at behandle opløsningen og præcipitatet ved centrifugering og/eller filtrering, hvorved kapselpolysaccharidet i opløsningen fastholdes, og det opløselige protein reduceres effektivt.
7. Fremgangsmåde ifølge et af kravene 1,4,5 eller 6, hvor detergentet er de-oxycholatnatrium.
8. Fremgangsmåde ifølge et af kravene 1, 4, 5 eller 6, hvor pH-værdien i trin (d) reduceres til mellem 4,5 og mindre end 5,5.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66954605P | 2005-04-08 | 2005-04-08 | |
| PCT/US2006/012134 WO2006110352A2 (en) | 2005-04-08 | 2006-03-31 | Separation of contaminants from streptococcus pneumoniae polysaccharide by ph manipulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1866342T3 true DK1866342T3 (da) | 2019-01-28 |
Family
ID=36660782
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18199835.2T DK3466982T3 (da) | 2005-04-08 | 2006-03-31 | Separation af forurenende kontaminanter fra streptococcus pneumoniae-polysaccharid ved ph-manipulation |
| DK06740302.2T DK1866342T3 (da) | 2005-04-08 | 2006-03-31 | Separation af forurenende kontaminanter fra streptococcus pneumoniae-polysaccharid ved ph-manipulation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18199835.2T DK3466982T3 (da) | 2005-04-08 | 2006-03-31 | Separation af forurenende kontaminanter fra streptococcus pneumoniae-polysaccharid ved ph-manipulation |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7718791B2 (da) |
| EP (2) | EP1866342B1 (da) |
| JP (1) | JP5049264B2 (da) |
| KR (1) | KR101317256B1 (da) |
| CN (1) | CN101155833B (da) |
| AR (1) | AR053843A1 (da) |
| AU (1) | AU2006234984B2 (da) |
| BR (1) | BRPI0607026B1 (da) |
| CA (1) | CA2604362C (da) |
| DK (2) | DK3466982T3 (da) |
| ES (2) | ES2707202T3 (da) |
| HU (1) | HUE050049T2 (da) |
| IL (1) | IL186366A (da) |
| MX (1) | MX2007012337A (da) |
| NZ (1) | NZ562719A (da) |
| PL (2) | PL1866342T3 (da) |
| PT (2) | PT3466982T (da) |
| SI (2) | SI3466982T1 (da) |
| TR (1) | TR201820018T4 (da) |
| WO (1) | WO2006110352A2 (da) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013201631C1 (en) * | 2006-10-10 | 2015-06-04 | Wyeth Llc | Purification of Streptococcus pneumoniae type 3 polysaccharides |
| RU2460539C2 (ru) * | 2006-10-10 | 2012-09-10 | Вайет | СПОСОБ ОЧИСТКИ ПОЛИСАХАРИДОВ Streptococcus pneumoniae 3 ТИПА (ВАРИАНТЫ) |
| PL2129693T3 (pl) | 2007-03-23 | 2017-07-31 | Wyeth Llc | Skrócony sposób oczyszczania do wytwarzania polisacharydów otoczkowych Streptococcus pneumoniae |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| PT2385981T (pt) * | 2008-12-18 | 2019-10-28 | Wyeth Llc | Método para controlar peso molecular de polissacárido de streptococcus pneumoniae com a utilização de carbono. |
| US8795689B2 (en) * | 2008-12-18 | 2014-08-05 | Wyeth Llc | Method for controlling Streptococcus pneumoniae serotype 19A polysaccharide molecular weight |
| EP2411048B1 (en) | 2009-03-24 | 2020-05-06 | GlaxoSmithKline Biologicals SA | Adjuvanting meningococcal factor h binding protein |
| JP5668049B2 (ja) | 2009-03-24 | 2015-02-12 | ノバルティス アーゲー | 髄膜炎菌ｈ因子結合タンパク質および肺炎球菌糖結合体の組み合わせ |
| BRPI1014494A2 (pt) | 2009-04-30 | 2016-08-02 | Coley Pharm Group Inc | vacina pneumocócica e usos da mesma |
| WO2011145108A2 (en) * | 2010-05-15 | 2011-11-24 | Serum Institute Of India Ltd. | Purification of capsular polysaccharides |
| EP2585106A1 (en) | 2010-06-25 | 2013-05-01 | Novartis AG | Combinations of meningococcal factor h binding proteins |
| CN102093963B (zh) * | 2010-11-26 | 2012-11-14 | 兰州生物制品研究所有限责任公司 | 富含磷壁酸的肺炎链球菌的培养方法 |
| CN102094053B (zh) * | 2010-11-26 | 2013-01-16 | 兰州生物制品研究所有限责任公司 | 肺炎链球菌c多糖的纯化方法 |
| JP6191082B2 (ja) | 2011-03-02 | 2017-09-06 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | より低用量の抗原および／またはアジュバントを有する混合ワクチン |
| EP2797624A1 (en) | 2011-12-29 | 2014-11-05 | Novartis AG | Adjuvanted combinations of meningococcal factor h binding proteins |
| JP2015510872A (ja) | 2012-03-07 | 2015-04-13 | ノバルティス アーゲー | Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤 |
| EP2822584A1 (en) | 2012-03-08 | 2015-01-14 | Novartis AG | Combination vaccines with tlr4 agonists |
| CN102660601B (zh) * | 2012-04-17 | 2015-10-28 | 江苏康泰生物医学技术有限公司 | 快速纯化细菌荚膜多糖的方法 |
| CN102660603B (zh) * | 2012-04-17 | 2015-03-25 | 江苏康泰生物医学技术有限公司 | 一种快速纯化细菌荚膜多糖的方法 |
| CN102660602B (zh) * | 2012-04-17 | 2015-03-25 | 江苏康泰生物医学技术有限公司 | 快速纯化细菌荚膜多糖的方法 |
| JP6324961B2 (ja) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | 血清群ｂ髄膜炎菌とｄ／ｔ／ｐとの組み合わせワクチン |
| EP2894225B1 (en) * | 2012-09-07 | 2017-11-22 | SK Chemicals Co., Ltd. | Production method for capsular polysaccharide having pneumococcal serotype |
| WO2014095771A1 (en) | 2012-12-18 | 2014-06-26 | Novartis Ag | Conjugates for protecting against diphtheria and/or tetanus |
| JP6612260B2 (ja) | 2014-01-21 | 2019-11-27 | ファイザー・インク | 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート |
| EP3616716A3 (en) | 2014-01-21 | 2020-05-06 | Pfizer Inc | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| SI3096786T1 (sl) | 2014-01-21 | 2021-09-30 | Pfizer Inc. | Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN107427568B (zh) | 2015-01-15 | 2021-12-14 | 辉瑞公司 | 用于肺炎球菌疫苗中的免疫原性组合物 |
| EP3292146A1 (en) | 2015-05-04 | 2018-03-14 | Pfizer Inc | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| PE20240927A1 (es) | 2015-07-21 | 2024-04-30 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos |
| CA3005524C (en) | 2015-11-20 | 2023-10-10 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| IL264553B2 (en) | 2016-08-05 | 2023-04-01 | Sanofi Pasteur Inc | A multivalent pneumococcal protein-polysaccharide conjugate preparation |
| TWI789357B (zh) | 2016-08-05 | 2023-01-11 | 南韓商Ｓｋ生物科技股份有限公司 | 多價肺炎球菌多醣-蛋白質共軛物組成物(二) |
| US10751402B2 (en) | 2016-11-09 | 2020-08-25 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| CA3048981A1 (en) | 2016-12-30 | 2018-07-05 | Sutrovax, Inc. | Polypeptide-antigen conjugates with non-natural amino acids |
| ES2911490T3 (es) | 2017-01-20 | 2022-05-19 | Pfizer | Composiciones inmunogénicas para su uso en vacunas antineumocócicas |
| WO2018144439A1 (en) | 2017-01-31 | 2018-08-09 | Merck Sharp & Dohme Corp. | Methods for making polysaccharide-protein conjugates |
| CN107043431B (zh) * | 2017-02-23 | 2020-06-30 | 上海瑞宙生物科技有限公司 | 细菌性荚膜多糖的纯化方法 |
| CN110337307A (zh) | 2017-02-24 | 2019-10-15 | 默沙东公司 | 增强肺炎链球菌多糖-蛋白缀合物的免疫原性 |
| JP7218358B2 (ja) | 2017-09-07 | 2023-02-06 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎球菌多糖体および免疫原性多糖体－キャリアタンパク質コンジュゲートでのその使用 |
| CA3074703A1 (en) | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| JP7369123B2 (ja) | 2017-12-06 | 2023-10-25 | メルク・シャープ・アンド・ドーム・エルエルシー | 肺炎球菌多糖類－タンパク質コンジュゲートを含む組成物およびその使用方法 |
| KR20210005158A (ko) | 2018-04-30 | 2021-01-13 | 머크 샤프 앤드 돔 코포레이션 | 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법 |
| KR20210002641A (ko) | 2018-04-30 | 2021-01-08 | 머크 샤프 앤드 돔 코포레이션 | 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법 |
| WO2020010000A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
| CN112543649A (zh) | 2018-07-04 | 2021-03-23 | Vaxcyte公司 | 免疫原性缀合物的改进 |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| JP2022512345A (ja) | 2018-12-12 | 2022-02-03 | ファイザー・インク | 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用 |
| MA54533A (fr) | 2018-12-19 | 2022-03-30 | Merck Sharp & Dohme | Compositions comprenant des conjugués polysaccharide-protéine de streptococcus pneumoniae et leurs méthodes d'utilisation |
| JP7239509B6 (ja) * | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| AU2020323498A1 (en) | 2019-07-31 | 2022-03-03 | Sk Bioscience Co., Ltd. | Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same |
| US20210070890A1 (en) * | 2019-09-06 | 2021-03-11 | Serum Institute Of India Private Limited | Method for obtaining purified bacterial polysaccharides |
| CA3192786A1 (en) | 2020-08-26 | 2022-03-03 | Pfizer Inc. | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
| GB202016165D0 (en) | 2020-10-12 | 2020-11-25 | Optivalent Ltd | Vaccine |
| AU2021373358A1 (en) | 2020-11-04 | 2023-06-01 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US20230405137A1 (en) | 2020-11-10 | 2023-12-21 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| JP2024517780A (ja) | 2021-05-03 | 2024-04-23 | ファイザー・インク | 細菌およびベータコロナウイルス感染症に対するワクチン接種 |
| WO2022234416A1 (en) | 2021-05-03 | 2022-11-10 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| MX2023013434A (es) | 2021-05-28 | 2023-12-12 | Pfizer Inc | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos. |
| US20220387576A1 (en) | 2021-05-28 | 2022-12-08 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| GB2614916A (en) | 2022-01-25 | 2023-07-26 | Optivalent Ltd | Intradermal vaccine complement |
| WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
| CN114853917A (zh) * | 2022-04-22 | 2022-08-05 | 兰州生物制品研究所有限责任公司 | 制备肺炎球菌荚膜多糖和肺炎球菌疫苗的方法 |
| WO2024084397A1 (en) | 2022-10-19 | 2024-04-25 | Pfizer Inc. | Vaccination against pneumoccocal and covid-19 infections |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| WO2024110839A2 (en) | 2022-11-22 | 2024-05-30 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2024116096A1 (en) | 2022-12-01 | 2024-06-06 | Pfizer Inc. | Pneumococcal conjugate vaccine formulations |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1115210A (en) * | 1977-11-28 | 1981-12-29 | Dennis J. Carlo | Pneumococcal vaccine |
| US4242501A (en) * | 1979-08-08 | 1980-12-30 | American Cyanamid Company | Purification of pneumococcal capsular polysaccharides |
| FR2495939B1 (fr) * | 1980-12-11 | 1985-10-11 | Merieux Inst | Procede de purification de polyosides de streptococcus pneumoniae et vaccin a base de polyosides ainsi purifies |
| BE889979A (fr) * | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
| US5714354A (en) * | 1995-06-06 | 1998-02-03 | American Home Products Corporation | Alcohol-free pneumococcal polysaccharide purification process |
| WO2000006738A2 (en) * | 1998-07-27 | 2000-02-10 | Microbial Technics Limited | NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE) |
| WO2001068903A1 (en) * | 2000-03-16 | 2001-09-20 | The Children's Hospital Of Philadelphia | Modulating production of pneumococcal capsular polysaccharide |
-
2006
- 2006-03-31 NZ NZ562719A patent/NZ562719A/en unknown
- 2006-03-31 TR TR2018/20018T patent/TR201820018T4/tr unknown
- 2006-03-31 SI SI200632381T patent/SI3466982T1/sl unknown
- 2006-03-31 ES ES06740302T patent/ES2707202T3/es active Active
- 2006-03-31 HU HUE18199835A patent/HUE050049T2/hu unknown
- 2006-03-31 PT PT181998352T patent/PT3466982T/pt unknown
- 2006-03-31 AU AU2006234984A patent/AU2006234984B2/en active Active
- 2006-03-31 WO PCT/US2006/012134 patent/WO2006110352A2/en active Application Filing
- 2006-03-31 CN CN200680011379XA patent/CN101155833B/zh active Active
- 2006-03-31 DK DK18199835.2T patent/DK3466982T3/da active
- 2006-03-31 PL PL06740302T patent/PL1866342T3/pl unknown
- 2006-03-31 US US11/396,108 patent/US7718791B2/en active Active
- 2006-03-31 PL PL18199835T patent/PL3466982T3/pl unknown
- 2006-03-31 ES ES18199835T patent/ES2808126T3/es active Active
- 2006-03-31 PT PT06740302T patent/PT1866342T/pt unknown
- 2006-03-31 SI SI200632310T patent/SI1866342T1/sl unknown
- 2006-03-31 KR KR1020077025986A patent/KR101317256B1/ko active IP Right Grant
- 2006-03-31 DK DK06740302.2T patent/DK1866342T3/da active
- 2006-03-31 CA CA2604362A patent/CA2604362C/en active Active
- 2006-03-31 EP EP06740302.2A patent/EP1866342B1/en active Active
- 2006-03-31 BR BRPI0607026-4A patent/BRPI0607026B1/pt active IP Right Grant
- 2006-03-31 JP JP2008505399A patent/JP5049264B2/ja active Active
- 2006-03-31 EP EP18199835.2A patent/EP3466982B1/en active Active
- 2006-03-31 MX MX2007012337A patent/MX2007012337A/es active IP Right Grant
- 2006-04-07 AR ARP060101391A patent/AR053843A1/es unknown
-
2007
- 2007-10-07 IL IL186366A patent/IL186366A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1866342T3 (da) | Separation af forurenende kontaminanter fra streptococcus pneumoniae-polysaccharid ved ph-manipulation | |
| JP6872649B2 (ja) | 莢膜Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ多糖の生産のための短縮された精製プロセス | |
| JP5843612B2 (ja) | 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）血清型１９Ａ多糖の分子量を制御するための方法 | |
| JP2015144614A (ja) | 二酸化炭素を用いて肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）多糖の分子量を制御するための方法 | |
| AU2013313794B2 (en) | Production method for capsular polysaccharide having pneumococcal serotype | |
| JP2010521972A5 (da) | ||
| TWI545192B (zh) | 用於製備肺炎鏈球菌血清型之莢膜多醣的方法 |